All In Biotech

Drug Trial Radar · NCT03844360

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Last checked: Nov 19, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,500

Planned (sponsor's estimate)

Start

Jan 31, 2016

Primary completion

Dec 31, 2025

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Wei ZhaoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
First posted
Feb 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 day, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.

Conditions

  • Hematological Neoplasms

Interventions

  • BortezomibDrug

    bortezomib was administered follow the doctor's advice.

  • EltrombopagDrug

    eltrombopag was administered follow the doctor's advice.

  • ImatinibDrug

    imatinib was administered follow the doctor's advice.

  • dasatinibDrug

    dasatinib was administered follow the doctor's advice.

  • PegaspargaseDrug

    pegaspargase was administered follow the doctor's advice.

  • Anti-Infective DrugsDrug

    anti-infective drugs was administered follow the doctor's advice.

  • PEGylated Recombinant Human Granulocyte Colony-Stimulating FactorDrug

    pegaspargase was administered follow the doctor's advice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. change of plasma concentration of bortezomibTime frame: at(0-0.5)h,(0.5-3)h,(24-48)h,(48-72)h hours after administration
  2. change of plasma concentration of eltrombopagTime frame: at (0.5-3)h,(3-6)h,(10-14)h,(20-24)h hours after oral administration
  3. change of plasma concentration of imatinibTime frame: at (0.5-2)h,(2-4)h,(10-14)h,(20-24)h hours after oral administration
  4. change of plasma concentration of dasatinibTime frame: at(0-0.5)h,(0.5-3)h,(10-14)h,(20-24)h hours after oral administration
  5. change of plasma concentration of pegaspargaseTime frame: at Day-1,Day(0-1),Day(3-5),Day(8-10),Day(13-14) after administration
  6. plasma concentration of anti-infective drugTime frame: through study completion, an average of 14 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Pediatrics, the Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Completed

  • State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Tanjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.